HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

nilutamide (Nilandron)

Also Known As:

Nilandron; 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)- 2,4-imidazolidinedione; Anandron; Aventis Behring Brand of Nilutamide; Aventis Brand of Nilutamide; Hoechst Brand of Nilutamide; RU 23908; RU 23908-10; RU-23908; 2,4-Imidazolidinedione, 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-

Networked: 106 relevant articles (13 outcomes, 17 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Azoles: 413
    - Imidazoles: 107
      - Imidazolidines: 6
        nilutamide: 106

Experts

1.	Labrie, Fernand: 3 articles (10/2012 - 12/2004)
2.	O'Brien, Peter: 2 articles (10/2014 - 03/2013)
3.	Arlen, Philip M: 2 articles (07/2008 - 03/2005)
4.	Gulley, James L: 2 articles (07/2008 - 03/2005)
5.	Décologne, Nathalie: 2 articles (01/2006 - 11/2004)
6.	Camus, Philippe: 2 articles (01/2006 - 11/2004)
7.	Ask, Kjetil: 2 articles (01/2006 - 11/2004)
8.	Pelczar, Hélène: 2 articles (01/2006 - 11/2004)
9.	Holme, Jørn A: 2 articles (01/2006 - 11/2004)
10.	Bussy, Ugo: 1 article (11/2014)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 01/01/1991 - "Results of this study suggest that Anandron may be a safe and effective treatment for patients with advanced prostatic cancer." 10/01/2005 - "Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer." 10/01/2005 - "Men with histologically confirmed prostate cancer not amenable to curative surgery or radiation therapy were eligible for the study if they had radiographic or PSA progression on at least one antiandrogen (not nilutamide) despite continued androgen suppression and standard antiandrogen withdrawal periods. " 01/01/1991 - "Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. " 06/01/2014 - "Nilutamide, a nonsteroidal anti-androgen drug, widely used in the treatment of prostate cancer, was subjected to hydrolytic, photolytic, thermal and oxidative stress conditions as per International Conference on Harmonization guidelines Q1A (R2). "
2.	Pain (Aches) 01/01/1995 - "Significant improvement or delayed deterioration in subjective parameters such as metastatic pain, performance status and urinary disorders strongly suggest (in the absence of validated questionnaires of quality of life at the time of this study) that orchiectomy plus nilutamide improves the quality of life as assessed by the subjective delay of progression, according to NPCP criteria, to an extent which outweighs the majority of adverse events." 01/01/1991 - "In three multicenter, randomized, double-blind placebo-controlled trials of castration and nilutamide involving 248 patients, the combination of nilutamide and castration decreased bone pain, improved performance status, and increased the number of patients with objective regression, compared with patients who were castrated but did not receive nilutamide. " 01/01/1993 - "In castrated patients the addition of nilutamide improves objective response rates, bone pain, urinary symptoms, tumour markers and time to disease progression. " 01/01/1991 - "In a short-term (29 days) comparison of nilutamide plus buserelin and buserelin plus placebo, nilutamide (300 mg/day), significantly reduced bone pain, and fewer patients experienced worsening pain than in the control group. " 04/01/1994 - "The combination of nilutamide and orchidectomy has a beneficial effect on pain of metastatic origin, levels of tumour markers, the objective response of disease and the time to disease progression. "
3.	Neoplasms (Cancer) 08/01/2002 - "When expressed as a percentage, the improvement in time to progression, overall and cancer specific survival in the Anandron treated patients was identical in both groups. " 01/01/1991 - "The administration of nilutamide to mice, castrated twenty-four hours before the inoculation of tumor cells, delayed the appearance of tumors and reduced their number. " 01/01/1991 - "This combined treatment "nilutamide plus castration" has been tested in an experimental androgen-dependent cancer model, the Shionogi tumor. " 11/01/2014 - "TFM is a pesticide used in the Laurential Great Lakes while niclosamide and nilutamide are used in cancer therapy. " 01/01/1991 - "Thus, nilutamide can prevent the tumor flare-up associated with the start of luteinizing hormone-releasing hormone (LH-RH) treatment, even though the endocrine responses are not affected. "
4.	Disease Progression 10/01/2005 - "All men received nilutamide 150 mg/day orally for > or = 8 weeks unless there was unacceptable toxicity or disease progression. " 01/01/1993 - "In castrated patients the addition of nilutamide improves objective response rates, bone pain, urinary symptoms, tumour markers and time to disease progression. " 12/20/1990 - "A randomized double-blind study with a 3-yr follow-up comparing the two arms "orchiectomy + Anandron (300 mg)" vs "orchiectomy + placebo" in 125 patients with stage D prostate cancer has confirmed the beneficial effects of the combined Anandron therapy on subjective parameters and on the best objective response (NPCP criteria), although these effects were not statistically significant, but failed to detect any improvement in time-to-disease progression or survival. " 04/01/1994 - "The combination of nilutamide and orchidectomy has a beneficial effect on pain of metastatic origin, levels of tumour markers, the objective response of disease and the time to disease progression. " 04/01/1994 - "In the group of patients treated with nilutamide 50% had complete or partial regression of disease compared with 33% of those who were given a placebo (P < 0.001); bone pain and levels of PAP and AP were improved or returned to normal significantly more frequently (P < 0.01); the odds of disease progression were significantly reduced (odds ratio 0.84, P = 0.05); the odds of death from cancer and from other causes were reduced but the difference was not statistically significant. "
5.	Carcinoma (Carcinomatosis) 01/12/2006 - "Nilutamide is a non-steroidal anti-androgen drug proposed in the treatment of metastatic prostatic carcinoma. " 11/15/2004 - "Nilutamide is a pneumotoxic and hepatotoxic nitroaromatic (R-NO2) antiandrogen used in the treatment of prostate carcinoma in man. " 08/01/1992 - "Nilutamide is a new, specific synthetic antiandrogen, released in several countries for the treatment of metastatic carcinoma of the prostate. " 12/01/1991 - "Nilutamide (N) is a potent antiandrogen used in the treatment of diffuse carcinoma of the prostate. " 08/01/1991 - "A total of 26 previously untreated patients with metastatic carcinoma of the prostate received the pure nonsteroidal antiandrogen nilutamide as a single agent. "

Related Drugs and Biologics

1.	nilutamide (Nilandron)
2.	Flutamide (Eulexin)
3.	Gonadotropin-Releasing Hormone (GnRH)
4.	bicalutamide (Casodex)
5.	Androgens
6.	Androgen Receptors (Androgen Receptor)
7.	Androgen Antagonists (Antiandrogens)
8.	Buserelin (Suprefact)
9.	Dehydroepiandrosterone (DHEA)
10.	Hormones

Related Therapies and Procedures

1.	Orchiectomy (Orchidectomy)
2.	Castration
3.	Life Support Care
4.	Oral Administration
5.	Radiotherapy